ArticleResearch square2026
Enzymatic Defluorination of Perfluorooctanoic Acid by an Evolutionarily Distinct Haloacid Dehalogenase.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Here, we demonstrate the successful purification of haloacid dehalogenase type II (HAD-II) enzyme, validating its catalytic capacity to directly mediate the cell-free defluorination of long-chain perfluorooctanoic acid (PFOA) by systematically cleaving the resilient C-F bond. While conventional remediation strategies rely on energy-intensive chemical methods, biological alternatives are limited to sluggish whole-microbiome consortia. We discovered a novel HAD-II enzyme from Achromobacter mucicolens harvested from PFAS-contaminated lacustrine sediment. Within 24 hours, the recombinant enzyme achieved cell-free PFOA defluorination, releasing 0.55 ppm of free fluoride (17% yield). Structural and phylogenetic analyses reveal that this HAD-II belongs to a deeply divergent lineage sharing only 25% sequence identity with the previously characterized Delftia homologue while preserving the core HAD-like catalytic fold. Comparative molecular docking elucidated that PFOA adopts a productive binding orientation near the conserved catalytic Asp15 within the A. mucicolens active-site pocket. Together, our work establishes a clean mechanistic paradigm for targeted environmental biotechnology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.